A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HW211026 Ointment After Single or Multiple Doses in Subjects With Actinic Keratosis
Latest Information Update: 12 Jan 2026
At a glance
- Drugs HW 211026 (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions
- Sponsors Hubei Biological Medicine Industrial Technology Institute
Most Recent Events
- 12 Jan 2026 New trial record